$4.93 Trillion is the total value of RA Capital Management's 70 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 38.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ASND | Sell | ASCENDIS PHARMA A/Ssponsored adr | $849,680,271 | +108629.6% | 6,957,179 | -8.1% | 17.23% | +3.4% |
| PCVX | Buy | VAXCYTE INC | $280,865,159 | +255350.4% | 5,857,459 | +27.9% | 5.70% | +142.8% |
| AVTE | AEROVATE THERAPEUTICS INC | $242,134,673 | +176618.7% | 8,263,982 | 0.0% | 4.91% | +68.0% | |
| Buy | DICE THERAPEUTICS INC | $213,686,023 | +202183.3% | 6,848,911 | +31.5% | 4.33% | +92.3% | |
| VRNA | Buy | VERONA PHARMA PLCsponsored ads | $165,089,079 | +266900.5% | 6,317,990 | +4.4% | 3.35% | +153.8% |
| RYTM | Buy | RHYTHM PHARMACEUTICALS INC | $160,627,871 | +119734.9% | 5,516,067 | +0.8% | 3.26% | +13.9% |
| DAWN | DAY ONE BIOPHARMACEUTICALS I | $151,514,185 | +107338.6% | 7,040,622 | 0.0% | 3.07% | +2.2% | |
| VOR | Buy | VOR BIOPHARMA INC | $151,280,052 | +341690.9% | 22,748,880 | +104.6% | 3.07% | +225.0% |
| BIIB | Sell | BIOGEN INC | $147,568,453 | +58850.7% | 532,892 | -43.2% | 2.99% | -44.0% |
| CYTEK BIOSCIENCES INC | $136,620,561 | +69261.5% | 13,381,054 | 0.0% | 2.77% | -34.1% | ||
| LEGN | Buy | LEGEND BIOTECH CORPsponsored ads | $121,616,252 | +127360.3% | 2,436,223 | +4.2% | 2.47% | +21.2% |
| RNA | Buy | AVIDITY BIOSCIENCES INC | $121,036,087 | +341877.5% | 5,454,533 | +151.7% | 2.46% | +225.2% |
| WVE | WAVE LIFE SCIENCES LTD | $120,414,063 | +193806.6% | 17,202,009 | 0.0% | 2.44% | +84.3% | |
| JANX | JANUX THERAPEUTICS INC | $114,192,381 | +97167.0% | 8,670,644 | 0.0% | 2.32% | -7.5% | |
| ETNB | Buy | 89BIO INC | $114,002,369 | +252890.0% | 8,955,410 | +15.1% | 2.31% | +140.6% |
| PEPGEN INC | $108,724,198 | +147146.9% | 8,131,952 | 0.0% | 2.20% | +40.0% | ||
| IMGN | Buy | IMMUNOGEN INC | $108,395,632 | +104202.8% | 21,853,958 | +0.5% | 2.20% | -0.9% |
| BLU | Buy | BELLUS HEALTH INC NEW | $102,360,158 | +85035.5% | 12,452,574 | +9.4% | 2.08% | -19.1% |
| INBX | New | INHIBRX INC | $94,959,283 | – | 3,853,867 | +100.0% | 1.93% | – |
| CLDX | CELLDEX THERAPEUTICS INC NEW | $92,482,750 | +158456.4% | 2,075,000 | 0.0% | 1.88% | +50.8% | |
| ITOS | ITEOS THERAPEUTICS INC | $86,269,068 | +102419.4% | 4,417,259 | 0.0% | 1.75% | -2.5% | |
| TVTX | Sell | TRAVERE THERAPEUTICS INC | $83,797,841 | +68982.6% | 3,984,681 | -19.1% | 1.70% | -34.3% |
| COGT | Buy | COGENT COMMUNICATIONS HLDGS | $69,354,000 | +115719.7% | 5,999,481 | +49.5% | 1.41% | +10.2% |
| ACRS | ACLARIS THERAPEUTICS INC | $69,275,635 | +99964.5% | 4,398,453 | 0.0% | 1.40% | -4.9% | |
| FULC | Buy | FULCRUM THERAPEUTICS INC | $69,203,134 | +122102.2% | 9,505,925 | +35.8% | 1.40% | +16.2% |
| New | ACRIVON THERAPEUTICS INC | $55,417,052 | – | 4,810,508 | +100.0% | 1.12% | – | |
| TYRA BIOSCIENCES INC | $54,997,050 | +86361.1% | 7,236,454 | 0.0% | 1.12% | -17.8% | ||
| ABOS | ACUMEN PHARMACEUTICALS INC | $52,762,174 | +53738.4% | 9,770,773 | 0.0% | 1.07% | -48.8% | |
| AKRO | AKERO THERAPEUTICS INC | $52,552,104 | +160841.1% | 958,980 | 0.0% | 1.07% | +52.9% | |
| ELIEM THERAPEUTICS INC | $48,263,616 | +113522.9% | 13,150,849 | 0.0% | 0.98% | +8.1% | ||
| GHRS | GH RESEARCH PLCordinary shares | $47,612,186 | +83549.0% | 4,898,373 | 0.0% | 0.97% | -20.4% | |
| ICOSAVAX INC | $47,350,706 | +251164.0% | 5,963,565 | 0.0% | 0.96% | +138.8% | ||
| RCKT | Buy | ROCKET PHARMACEUTICALS INC | $47,107,906 | +139977.0% | 2,407,149 | +14.2% | 0.96% | +33.2% |
| NKTX | NKARTA INC | $46,752,723 | +45416.5% | 7,805,129 | 0.0% | 0.95% | -56.7% | |
| New | NEWAMSTERDAM PHARMA COMPANYordinary shares | $43,600,000 | – | 4,000,000 | +100.0% | 0.88% | – | |
| RXSIGHT INC | $38,678,925 | +105484.9% | 3,052,796 | 0.0% | 0.78% | +0.4% | ||
| AN2 THERAPEUTICS INC | $35,961,617 | +54732.9% | 3,773,517 | 0.0% | 0.73% | -47.9% | ||
| ALPN | Buy | ALPINE IMMUNE SCIENCES INC | $32,320,655 | +102937.0% | 4,397,368 | +0.9% | 0.66% | -2.1% |
| GERN | Sell | GERON CORP | $31,292,321 | +44288.8% | 12,930,711 | -57.1% | 0.64% | -57.8% |
| DSGN | Buy | DESIGN THERAPEUTICS INC | $30,484,830 | +65645.4% | 2,971,231 | +7.1% | 0.62% | -37.5% |
| HILLEVAX INC | $29,445,118 | +97792.6% | 1,760,019 | 0.0% | 0.60% | -7.0% | ||
| KNTE | KINNATE BIOPHARMA INC | $26,011,278 | +50946.5% | 4,264,144 | 0.0% | 0.53% | -51.4% | |
| SBTX | New | ARS PHARMACEUTICALS INC | $25,672,553 | – | 3,009,678 | +100.0% | 0.52% | – |
| VRDN | VIRIDIAN THERAPEUTICS INCsponsored ads | $25,704,800 | +142316.8% | 880,000 | 0.0% | 0.52% | +35.3% | |
| CELC | New | CELCUITY INC | $19,614,014 | – | 1,400,001 | +100.0% | 0.40% | – |
| New | SOLID BIOSCIENCES INC | $18,433,419 | – | 3,426,286 | +100.0% | 0.37% | – | |
| DA32 LIFE SCNCE | $14,992,500 | +102623.5% | 1,500,000 | 0.0% | 0.30% | -2.3% | ||
| SCPH | New | SCPHARMACEUTICALS INC | $13,314,002 | – | 1,856,904 | +100.0% | 0.27% | – |
| IMRA | New | IMARA INC | $13,295,461 | – | 3,250,724 | +100.0% | 0.27% | – |
| Buy | TENAYA THERAPEUTICS INC | $12,195,641 | +262397.7% | 6,067,483 | +278.7% | 0.25% | +149.5% | |
| EYPT | EYEPOINT PHARMACEUTICALS INC | $11,796,771 | +44149.0% | 3,370,506 | 0.0% | 0.24% | -58.0% | |
| ARYA SCIENCES ACQUISITN CORP | $10,090,000 | +102859.2% | 1,000,000 | 0.0% | 0.20% | -1.9% | ||
| HOWL | WEREWOLF THERAPEUTICS INC | $8,798,356 | +45355.4% | 4,291,881 | 0.0% | 0.18% | -56.9% | |
| AADI BIOSCIENCE INC | $7,572,497 | +90697.3% | 590,218 | 0.0% | 0.15% | -13.5% | ||
| CNCE | CONCERT PHARMACEUTICALS INC | $6,355,649 | +87059.2% | 1,088,296 | 0.0% | 0.13% | -17.3% | |
| HSAQ | HEALTH SCIENCES ACQ CORP 2 | $6,090,624 | +100704.8% | 610,283 | 0.0% | 0.12% | -3.9% | |
| CNTB | CONNECT BIOPHARMA HLDGS LTDads | $6,066,792 | +67174.3% | 6,991,003 | 0.0% | 0.12% | -35.9% | |
| ATHA | Buy | ATHIRA PHARMA INC | $5,963,721 | +106815.0% | 1,881,300 | +0.2% | 0.12% | +1.7% |
| STSA | SATSUMA PHARMACEUTICALS INC | $5,322,827 | +14899.8% | 5,914,252 | 0.0% | 0.11% | -85.7% | |
| CVRX | CVRX INC | $5,046,250 | +196558.2% | 275,000 | 0.0% | 0.10% | +85.5% | |
| BDTX | BLACK DIAMOND THERAPEUTICS I | $4,661,827 | +106407.4% | 2,589,904 | 0.0% | 0.10% | +2.2% | |
| DBVT | Sell | DBV TECHNOLOGIES S Asponsored adr | $2,997,204 | +45360.4% | 1,958,957 | -47.4% | 0.06% | -56.7% |
| Sell | IO BIOTECH INC | $2,592,698 | +51393.5% | 1,127,260 | -39.3% | 0.05% | -50.5% | |
| Sell | THIRD HARMONIC BIO INC | $2,299,154 | +3387.1% | 534,687 | -84.6% | 0.05% | -96.7% | |
| FUSN | FUSION PHARMACEUTICALS INC | $2,078,975 | +104528.8% | 659,992 | 0.0% | 0.04% | 0.0% | |
| ACHL | Sell | ACHILLES THERAPEUTICS PLCsponsored ads | $1,447,051 | +12668.5% | 1,607,834 | -67.9% | 0.03% | -88.0% |
| NSTG | Sell | NANOSTRING TECHNOLOGIES | $1,146,883 | +1851.3% | 143,900 | -96.9% | 0.02% | -98.2% |
| IMUX | New | IMMUNIC INC | $885,058 | – | 632,184 | +100.0% | 0.02% | – |
| New | NEWAMSTERDAM PHARMA COMPANY*w exp 11/22/202 | $289,433 | – | 333,333 | +100.0% | 0.01% | – | |
| ENTX | Sell | ENTERA BIO LTD | $216,055 | +9874.8% | 295,966 | -85.8% | 0.00% | -91.3% |
| AGLE | Exit | AEGLEA BIOTHERAPEUTICS INC | $0 | – | -10,439 | -100.0% | 0.00% | – |
| APTX | Exit | APTINYX INC | $0 | – | -1,954,698 | -100.0% | -0.02% | – |
| BOLT | Exit | BOLT BIOTHERAPEUTICS INC | $0 | – | -533,432 | -100.0% | -0.02% | – |
| SNSE | Exit | SENSEI BIOTHERAPEUTICS | $0 | – | -683,529 | -100.0% | -0.02% | – |
| Exit | PYXIS ONCOLOGY INC | $0 | – | -764,653 | -100.0% | -0.03% | – | |
| SYBX | Exit | SYNLOGIC INC | $0 | – | -4,618,415 | -100.0% | -0.09% | – |
| MGTA | Exit | MAGENTA THERAPEUTICS INC | $0 | – | -3,588,081 | -100.0% | -0.11% | – |
| SLDB | Exit | SOLID BIOSCIENCES INC | $0 | – | -12,367,873 | -100.0% | -0.12% | – |
| FVAM | Exit | 5 01 ACQUISITION CORP | $0 | – | -750,000 | -100.0% | -0.16% | – |
| FLACU | Exit | FRAZIER LIFESCIENCES ACQU CO | $0 | – | -1,000,000 | -100.0% | -0.21% | – |
| Exit | PARDES BIOSCIENCES INC | $0 | – | -6,175,038 | -100.0% | -0.24% | – | |
| BLSA | Exit | BCLS ACQUISITION CORP | $0 | – | -1,250,000 | -100.0% | -0.27% | – |
| RLAY | Exit | RELAY THERAPEUTICS INC | $0 | – | -717,618 | -100.0% | -0.34% | – |
| PMVP | Exit | PMV PHARMACEUTICALS INC | $0 | – | -1,710,265 | -100.0% | -0.43% | – |
| MIST | Exit | MILESTONE PHARMACEUTICALS IN | $0 | – | -2,246,503 | -100.0% | -0.44% | – |
| ACET | Exit | ADICET BIO INC | $0 | – | -2,059,372 | -100.0% | -0.62% | – |
| VERA | Exit | VERA THERAPEUTICS INCcl a | $0 | – | -1,578,820 | -100.0% | -0.72% | – |
| TIL | Exit | INSTIL BIO INC | $0 | – | -7,670,793 | -100.0% | -0.79% | – |
| ENTA | Exit | ENANTA PHARMACEUTICALS INC | $0 | – | -896,724 | -100.0% | -0.99% | – |
| RLMD | Exit | RELMADA THERAPEUTICS INC | $0 | – | -2,000,000 | -100.0% | -1.58% | – |
| FMTX | Exit | FORMA THERAPEUTICS HLDGS INC | $0 | – | -9,011,651 | -100.0% | -3.84% | – |
Signatures
The EDGAR filing(s) were signed by:
- Rajeev Shah — Authorized Signatory
About RA Capital Management
RA Capital Management is a Boston-based investment management firm that specializes in the healthcare sector. The firm was founded in 2001 by Peter Kolchinsky, a former biotech analyst at Lehman Brothers. Since then, RA Capital has grown to become one of the most respected healthcare investment firms in the world, with over $5 billion in assets under management.
The firm's investment strategy is focused on identifying and investing in companies that are developing innovative therapies and technologies that have the potential to transform the healthcare industry. RA Capital's team of experienced analysts and portfolio managers conduct extensive research and due diligence to identify the most promising investment opportunities in the healthcare sector.
RA Capital's portfolio includes a diverse range of companies, from early-stage startups to established biotech and pharmaceutical companies. Some of the notable companies in RA Capital's portfolio include Moderna, a biotech company that is developing a COVID-19 vaccine, and Intellia Therapeutics, a gene editing company that is developing therapies for genetic diseases.
Peter Kolchinsky, the founder and CEO of RA Capital, is a well-respected figure in the healthcare investment community. He is a frequent speaker at industry conferences and has authored several books on biotech investing. Other key members of RA Capital's management team include Rajeev Shah, the firm's COO, and Derek DiRocco, the Chief Investment Officer.
Overall, RA Capital Management is a highly respected investment firm that has a proven track record of identifying and investing in innovative healthcare companies. Investors who are interested in the healthcare sector may want to consider RA Capital as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
- RA Capital Management holdings (13F-HR)
- RA Capital Management significant holdings (13D/G)
- RA Capital Management ownership history
- RA Capital Management portfolio value
- RA Capital Management insiders transactions
- RA Capital Management filings
- Similar filers BETA
Compare quarterly holdings
Export RA Capital Management's holdings